Organization
Kind Pharmaceuticals
7 clinical trials
Clinical trial
A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Efficacy and Safety Study of AND017 for the Treatment of Anemia Due to Lower Risk Myelodysplastic Syndromes (MDS)Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Cancer-Related Anemia Patients Receiving ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Anemia of Cancer in Patients Not Receiving ChemotherapyStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Pilot Phase II Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral AND017 to Treat Anemia in Nondialysis-Dependent Chronic Kidney Disease (NDD-CKD) PatientsStatus: Completed, Estimated PCD: 2023-07-05